Sign inJoin waitlistJoin the waitlist

Brittany Ragon

Co-Associate Leader · Wake Forest University Baptist Medical Center

Credentials: · · · · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2014–2017
Internal Medicine
Vanderbilt University Medical Center
2011–2014
Columbia Univ Coll of Phys & Surgeons
2007–2011
Clemson University
2003–2007

Research

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
Clinical Lymphoma · 2019 · First of 14 authors · 58 citations
Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation
Biology of Blood and Marrow Transplantation · 2019 · 55 citations
Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy
JCO Oncology Practice · 2022 · 53 citations

Michael Grunwald
10 papers
Jing Ai
8 papers
Thomas Knight
8 papers
Aleksander Chojecki
7 papers
Srinivasa Sanikommu
7 papers · 4 as a fellow
Edward Copelan
6 papers
Nilay Shah
6 papers
Belinda Copelan
3 papers
GB
Gautam Borthakur
3 papers
Guillermo Garcia-Manero
3 papers
Justin Arnall
3 papers
Nilanjan Ghosh
3 papers

Clinical trials

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Principal investigator · Recruiting
Wake Forest University Health Sciences
2025–2030
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027